Pairing a novel enhancer with transfection reagents to enable high-titer rAAV production
Sponsor
With the success of cell and gene therapies and exponentially increasing demand, the second wave of viral vector manufacturing is focused on large-scale suspension cell culture. Upstream manufacturing processes for recombinant adeno-associated virus (AAV) and lentivirus (LV) are largely dependent on transient transfection of multiple plasmid DNA constructs encoding essential viral proteins. To produce the virus needed for these therapies, processes must be adapted to bioreactor scale for cGMP production. In response to this need, Mirus Bio has established solutions including a novel transfection reagent that increases AAV and LV titers 2-10-fold over existing technologies, and a unique enhancer that increases titer over the reagent up to 4X.
This webinar will adopt a roundtable format with a panel comprising end users as well as a Mirus Bio senior research scientist. Join us for open discussion and sharing of learnings on how to address productivity hurdles in the viral vector process workflow.
Attend this webinar to:
- Understand how you can achieve your viral vector process productivity milestones
- Find out how the VirusGEN® platform increases production across multiple transfection workflows and a variety of AAV serotypes
- Enable reductions in cost per dose for cell and gene therapies
- Streamline your journey from a technical evaluation through implementation
SPEAKERS
You might also like
Same-section spatial multiomics: a platform for detailed analysis of the solid tumor TME
Quadplex dPCR as a tool to analyze genome integrity and heterogeneity in gene therapy drug products
Precision in production: optimizing monitoring and quality control for high-value plasmids
Advancing cell therapy: innovations in polymer-based encapsulation and delivery
